H.R. 6802 · 118th Congress (2023–2025)
RAPID Reserve Act
This bill requires the Department of Health and Human Services to contract with drug manufacturers to ensure adequate supplies of critical drugs that have vulnerable supply chains. (Under the bill, drugs are considered critical if they are likely to be needed during a public health emergency or if a shortage would pose a significant threat to the health care system or at-risk populations.)
Contracted drug manufacturers must agree to (1) maintain at least a 6-month reserve of the active ingredient in a critical drug and of the finished product and to regularly replenish these reserves, (2) produce the ingredient and drug in a manner and quantity as specified in the contract, and (3) agree to transfer portions of the reserve, if necessary, to other manufacturers to meet manufacturing needs and allow HHS to control the allocation of reserves in the event of a public health emergency or other threat.
HHS must publish a list of critical drugs and issue guidance on the criteria for determining this list and awarding contracts. HHS must give preference to domestic manufacturers for contracts.
In addition, the Government Accountability Office must report on the capacity of domestic manufacturing with respect to critical drugs, including the ability to manufacture different dosage forms and drugs with various characteristics.
Show official title
To improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 6802’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Angie Craig (D-MN-2)
- Cosponsors
6 cosponsors
2 original · 4 later
1 R · 5 D
- Rep. Abigail Davis Spanberger (D-VA-7)· Original · Dec 14, 2023
- Rep. Jefferson Van Drew (R-NJ-2)· Original · Dec 14, 2023
- Del. Eleanor Holmes Norton (D-DC)· Later · Mar 7, 2024
- Rep. Chrissy Houlahan (D-PA-6)· Later · Mar 12, 2024
- Rep. Elissa Slotkin (D-MI-7)· Later · May 6, 2024
- Rep. Darren Soto (D-FL-9)· Later · Aug 16, 2024
- Policy area
- Health
- Subjects
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Government information and archives
- Government studies and investigations
- Manufacturing
- Prescription drugs
- Public contracts and procurement
- Strategic materials and reserves
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Dec 14, 2023 – Dec 15, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (3)
RAPID Reserve Act
Display title, Short title · Introduced in House
Rolling Active Pharmaceutical Ingredient and Drug Reserve Act
Short title · Introduced in House
To improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.
Official title · Introduced in House